Advertisement

Topics

Gilotrif (afatinib)

15:47 EST 24th November 2017 | BioPortfolio

GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

Website: http://www.gilotrif.com/

Manufacturer: Boehringer Ingelheim

Read prescription information

Quick Search
Advertisement
 

review and buy Gilotrif (afatinib) market research data and corporate reports here